|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2007-7-19
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ArduinoJean MarieJM,
pubmed-author:DuvicMadeleineM,
pubmed-author:FossFrancine MFM,
pubmed-author:FrankelStanley RSR,
pubmed-author:KimYoun HYH,
pubmed-author:KuzelTimothy MTM,
pubmed-author:LeyG DGD,
pubmed-author:OlsenElise AEA,
pubmed-author:PachecoTheresa RTR,
pubmed-author:ParkerSareetaS,
pubmed-author:RickerJustin LJL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3109-15
|
|
pubmed:dateRevised |
2008-5-30
|
|
pubmed:meshHeading |
pubmed-meshheading:17577020-Administration, Oral,
pubmed-meshheading:17577020-Adult,
pubmed-meshheading:17577020-Aged,
pubmed-meshheading:17577020-Aged, 80 and over,
pubmed-meshheading:17577020-Confidence Intervals,
pubmed-meshheading:17577020-Dose-Response Relationship, Drug,
pubmed-meshheading:17577020-Drug Administration Schedule,
pubmed-meshheading:17577020-Drug Resistance, Neoplasm,
pubmed-meshheading:17577020-Female,
pubmed-meshheading:17577020-Follow-Up Studies,
pubmed-meshheading:17577020-Humans,
pubmed-meshheading:17577020-Hydroxamic Acids,
pubmed-meshheading:17577020-Lymphoma, T-Cell, Cutaneous,
pubmed-meshheading:17577020-Male,
pubmed-meshheading:17577020-Maximum Tolerated Dose,
pubmed-meshheading:17577020-Middle Aged,
pubmed-meshheading:17577020-Neoplasm Staging,
pubmed-meshheading:17577020-Probability,
pubmed-meshheading:17577020-Salvage Therapy,
pubmed-meshheading:17577020-Skin Neoplasms,
pubmed-meshheading:17577020-Survival Analysis,
pubmed-meshheading:17577020-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
|
|
pubmed:affiliation |
Duke University, Durham, NC, USA. olsen001@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
